Does your post COVID-19 patients has persistent cough or breathlessness?
If yes, please consider to recruit the patient into this study!

TM02® -PACOVIR



This is a randomised, double-blind, placebo-controlled trial in evaluating the efficacy of the Tiger Milk Mushroom TM02®, in COVID-19 patients with respiratory conditions.

PACS patients:
History of COVID-19 infection at least 3 weeks prior & ongoing respiratory symptoms



R

- Standard of care + **placebo**
- Standard of care + **TM02®**

Final follow up at week 12

6 weeks

6 weeks of daily placebo/TM02® ; 12 weeks of follow up with clinical symptoms, blood test, urine test, 6- minute walk test, lung function test and chest X-ray or CT scan.

Risks and Benefits:

There are no reported adverse events from the existing randomised controlled trial. Patients will be given RM150 per study visit (5 visits in total). Patients may have early clinical improvement of respiratory symptoms and better quality of life.

Inclusion Criteria:

1. Patients with diagnosis of COVID-19 confirmed by reverse-transcriptase-polymerase chain reaction (RT-PCR) or Rapid Test Kit- Antigen Test (RTK-Ag) irrespective of CT value
2. Patients with mild to severe disease or Category 2 to 4 disease.
3. Patients with ongoing respiratory conditions such as persistent cough or breathlessness for at least 3 weeks that is related to COVID-19 infection based on the investigator's clinical assessment.
4. Age ⩾ 18

Exclusion Criteria:

1. Patients with known or clinically suspected congestive heart failure, chronic lung disease (interstitial lung disease, chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis), secondary bacteria or fungal infection, active pulmonary tuberculosis, advanced malignancy, obesity hypoventilation syndrome, on immunosuppressive therapy, or with any kidney disorder that may potentially affect the study endpoint.
2. Pregnancy
3. Age < 18
4. Any previous experimental treatment for COVID-19
5. With preexisting Human Immunodeficiency Virus infection
6. Female subjects of childbearing potential not willing to use contraceptive methods.
7. Male subjects not willing to use contraceptive methods.

Contact Us!

Feel free to contact us to learn more:

Dr. Wong Chee Kuan
Head of Respiratory Unit,
Consultant Respiratory Physician
University of Malaya Medical Centre.
Telephone number (Mobile): +6017-8712807
Email: ckwong@ummc.edu.my

Dr. Sia Leng Cheng
Clinical specialist
University of Malaya Medical Centre.
Telephone number: +60379494422
Email: lcsia@ummc.edu.my

Mr. Tan Hao Dong
Study Coordinator
University of Malaya Medical Centre.
Telephone number: +60183830436
Email: hdt963hn@gmail.com